NRIX Slumps 35% After-Hours — What's Driving The Selloff?

What happened

Sanofi told Nurix Therapeutics it is ending the early-stage first-in-human trial of SAR448272, an experimental oral drug licensed from Nurix, and terminating the program. The drug was being studied for type 2 inflammatory and autoimmune conditions, including atopic dermatitis and asthma.

Confirmed

Global impact / market context

The termination removes a potential source of future payments to Nurix: the company had been eligible for roughly $455 million in development, regulatory, and commercial milestones, plus royalties if the drug reached sales. That weakens the program’s possible contribution to future revenue, though Nurix says its cash runway guidance is unchanged.

Analyst inference

The reported after-hours share decline followed the loss of one partnered drug program and its associated payment potential. Nurix said it retains eligibility for milestones and royalties on other licensed programs if Sanofi advances them, and expects its existing cash to fund operations into the second half of 2029.

Confirmed

What to watch

1. Watch for Nurix updates on whether Sanofi advances other licensed programs, because doing so could preserve potential milestone payments and royalties despite this program’s termination. Analyst inference
2. Track Nurix’s future disclosures about cash and its stated runway into the second half of 2029; the company says this decision does not change that guidance. Confirmed
3. Look for further detail on the terminated program’s financial contribution, if disclosed, to assess how much of Nurix’s expected future revenue depended on its milestones and royalties. Analyst inference

Evidence

• stocktwits.com